May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
3 citations
,
September 2025 in “Frontiers in Cardiovascular Medicine” Women with PCOS have a higher risk of heart disease.
1 citations
,
October 2025 in “Journal of Personalized Medicine” Weight loss improves PCOS symptoms and overall health.
May 2026 in “International Journal of Innovative Technologies in Social Science” PCOS is best managed with personalized lifestyle changes, medications, and sometimes surgery.
February 2024 in “Journal of Education, Health and Sport” Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
December 2019 in “Orvostudományi Értesítö” Lifestyle changes, medications, and fertility treatments can improve PCOS symptoms and prevent complications.
May 2024 in “International Journal of Dermatology” More research is needed to understand if GLP-1 agonists affect hair health.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
June 2026 in “Frontiers in Nutrition” GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.
February 2025 in “Journal of Neonatal Surgery” Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.
20 citations
,
August 2022 in “Archives of Medical Science” The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
June 2026 in “Dermatology and Therapy” GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
January 2025 in “PROTEOMICS” Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
September 2025 in “Cureus” GLP-1 receptor agonists may cause hair loss, but more research is needed.
April 2026 in “Open MIND” GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.